155 related articles for article (PubMed ID: 35023190)
41. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.
Mei M; Thomas S; Chen R
BioDrugs; 2014 Jun; 28(3):245-51. PubMed ID: 24258497
[TBL] [Abstract][Full Text] [Related]
42. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
[TBL] [Abstract][Full Text] [Related]
43. Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma.
Van de Wyngaert Z; Coppo P; Cervera P; Fabiani B; Lemonnier MP; Corre E; Marjanovic Z; Aoudjhane M; Mohty M; Duléry R
Eur J Haematol; 2021 Apr; 106(4):467-472. PubMed ID: 33320379
[TBL] [Abstract][Full Text] [Related]
44. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
[TBL] [Abstract][Full Text] [Related]
45. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.
Gibb A; Jones C; Bloor A; Kulkarni S; Illidge T; Linton K; Radford J
Haematologica; 2013 Apr; 98(4):611-4. PubMed ID: 23065511
[TBL] [Abstract][Full Text] [Related]
46. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
Bossard C; Dobay MP; Parrens M; Lamant L; Missiaglia E; Haioun C; Martin A; Fabiani B; Delarue R; Tournilhac O; Delorenzi M; Gaulard P; de Leval L
Blood; 2014 Nov; 124(19):2983-6. PubMed ID: 25224410
[TBL] [Abstract][Full Text] [Related]
47. CD30: seeing is not always believing.
Blum KA
Blood; 2015 Feb; 125(9):1358-9. PubMed ID: 25721040
[TBL] [Abstract][Full Text] [Related]
48. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.
Lewis DJ; Talpur R; Huen AO; Tetzlaff MT; Duvic M
JAMA Dermatol; 2017 Dec; 153(12):1302-1306. PubMed ID: 28980004
[TBL] [Abstract][Full Text] [Related]
49. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
50. Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma.
Lai CM; Horowitz S
Expert Rev Hematol; 2013 Aug; 6(4):361-73. PubMed ID: 23991923
[TBL] [Abstract][Full Text] [Related]
51. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
[TBL] [Abstract][Full Text] [Related]
52. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
Berger GK; McBride A; Lawson S; Royball K; Yun S; Gee K; Bin Riaz I; Saleh AA; Puvvada S; Anwer F
Crit Rev Oncol Hematol; 2017 Jan; 109():42-50. PubMed ID: 28010897
[TBL] [Abstract][Full Text] [Related]
53. Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies.
Kim DH; Vega F
Blood; 2022 Feb; 139(6):951. PubMed ID: 35142847
[No Abstract] [Full Text] [Related]
54. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
[TBL] [Abstract][Full Text] [Related]
55. Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies.
Chen R; Wang F; Zhang H; Chen B
Drug Des Devel Ther; 2015; 9():2277-83. PubMed ID: 25945039
[TBL] [Abstract][Full Text] [Related]
56. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
Plattel WJ; Bergamasco A; Trinchese F; Gavini F; Bent-Ennakhil N; Zomas A; Castillon G; Arredondo-Bisono T; Cristarella T; Moride Y; von Tresckow B
Leuk Lymphoma; 2021 Dec; 62(14):3320-3332. PubMed ID: 34323643
[TBL] [Abstract][Full Text] [Related]
58. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
Kort J; Chidiac A; El Sayed R; Massoud R; Nehme R; Bazarbachi A; El-Cheikh J
Leuk Lymphoma; 2020 Jul; 61(7):1732-1735. PubMed ID: 32090673
[TBL] [Abstract][Full Text] [Related]
59. Demyelinating neuropathy and local toxicity caused by extravasated Brentuximab vedotin.
Hoffmann JC; Soliman M; Koch JC; Liman J; Schön MP; Mitteldorf C
J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):e626-e628. PubMed ID: 32311792
[No Abstract] [Full Text] [Related]
60. Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.
Fukuhara N; Yamamoto G; Tsujimura H; Chou T; Shibayama H; Yanai T; Shibuya K; Izutsu K
Leuk Lymphoma; 2020 Jan; 61(1):176-180. PubMed ID: 31437057
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
